Dopaminergic Neurotransmission in Schizophrenia, Patients at Risk and Healthy Subjects

Ludwig Maximilian University of Munich

Status: Completed

Conditions: Schizophrenia

Treatments: Procedure: IBZM-SPECT (bolus and constant infusion paradigm)

Study type: Interventional

Funder types: Other

Identifiers

NCT00166322

EK076/03

DYN-SPECT-Pogarell

Details and patient eligibility

About

This study is an investigation of the dopaminergic neurotransmission in patients with schizophrenia, patients at risk for the development of schizophrenia, and healthy controls using an iodobenzamide-single photon emission computed tomography (IBZM-SPECT) imaging technique under amphetamine challenge.

Enrollment: 35 patients

Sex: All

Ages: 18 to 70 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Clinical diagnosis of schizophrenia (currently unmedicated)
• Subjects at risk for the development of schizophrenia (prodromal symptoms)
• Healthy subjects
• Written informed consent

Exclusion criteria

• Neurological or severe somatic disorders
• Women during pregnancy or lactation
• Occupational exposition to radiation > 15mSv
• Medication known to interfere with IBZM
• Contraindications for the use of amphetamine challenge

Trial design

Primary purpose: Diagnostic

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)